Summary of changes FKBPL and CD44 changes throughout gestation in pregnancies...
Summary of changes FKBPL and CD44 changes throughout gestation in pregnancies complicated by pre-eclampsia.

Source: Oxford Press

Preeclampsia

Novel biomarker discovery could help mother and baby

The discovery of two novel biomarkers, called FKBPL and CD44, has the potential to change the way preeclampsia is managed according to research published in the Journal of Clinical Endocrinology and Metabolism. Preeclampsia can cause high blood pressure and organ failure in mothers and lead to preterm births and even stillbirth. It is a devastating disorder that occurs very suddenly in the second half of pregnancy and causes severe health problems for both mother and baby. Preeclampsia also increases the risk of developing life-long chronic diseases such as diabetes and heart disease.

Senior author, Dr. Lana McClements from the University of Technology Sydney, said the biomarkers can be used to diagnose and assess the risk of getting preeclampsia in both early and late pregnancy, "in women who otherwise appear healthy".

"There are two main types of preeclampsia: early-onset preeclampsia diagnosed before 34 weeks of a pregnancy and late-onset preeclampsia diagnosed from 34 weeks onwards," McClements said.

"The vast majority of the current screening and monitoring strategies are focused on early-onset preeclampsia, which comprises only 10-15% of all preeclampsia cases, whereas late preeclampsia has been largely neglected," she said.

The researchers say the two biomarkers are particularly useful for diagnosing cases of late-onset preeclampsia, between the second and third trimester, a period that currently lacks reliable biomarkers.

" The biomarkers allow the prediction of irregular placenta or maternal vascular function, which are key underlying causes of preeclampsia.

"This could lead to the early diagnosis and prevention of severe preeclampsia and associated complications including death, therefore also giving insight into disease mechanisms and possible treatment targets," McClements said.

Recommended article

Photo

Clinical trials beginning

Possible preeclampsia treatment is on the way

For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia – a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies. Now the researchers have published a study in the journal Scientific Reports that opens up opportunities for further…

The research also has potential to enhance the development of therapeutics to treat preeclampsia because the increase in one of the biomarkers, FKBPL, can be inhibited by mesenchymal stem cells potentially stopping the development of preeclampsia.

" This is why we are so excited by the discovery. In addition to their use in diagnosis, FKBPL and CD44 also show potential as drug and cell therapy targets of emerging treatments for preeclampsia, which offers hope for a future cure to this terrible disorder," McClements said.


Source: University of Technology, Sidney

03.07.2020

Read all latest stories

Related articles

Photo

Cardiology congress

ESC 2018: At the heart of research

When delegates from around 150 countries converge on Munich for ESC Congress 2018 they will no doubt reflect on what they themselves eat. Yes, nutrition is up for debate, questioning, for example,…

Photo

Tailor-made therapies

Diabetes care enters precision medicine

A new joint report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) presents the largest venture ever on precision medicine in diabetes. The…

Photo

Profiling the coronavirus

Risk factors for severe and fatal COVID-19 cases identified

Age, male sex, obesity, and underlying illness have emerged as risk factors for severe and fatal cases of COVID-19 in the UK, according to the largest cohort study to date published by The BMJ. As…

Related products

Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH